Bollard Group’s Alexion Pharmaceuticals ALXN Stock Holding History

Bollard Group’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-424	Closed	-$78K	–	431
2021 Q2	$78K	Hold	424	–	–	﹤0.01%	310
2021 Q1	$65K	Hold	424	–	–	﹤0.01%	327
2020 Q4	$66K	Hold	424	–	–	﹤0.01%	316
2020 Q3	$49K	Hold	424	–	–	﹤0.01%	326
2020 Q2	$48K	Buy	+424	New	+$45K	﹤0.01%	349

Other funds holding ALXN

BCI

Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return

NICM

Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return

TAIM

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CFO

CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Bollard Group's ALXN Position: Q3 2021 in Review

Bollard Group sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 424 shares — an estimated $78K sold.

Bollard Group first reported a position in ALXN in Q2 2020 and held it in 5 quarters. The position peaked at $78K in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

Bollard Group reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Bollard Group sold 424 Alexion Pharmaceuticals shares in Q3 2021, an estimated $78K.
Bollard Group first reported a position in Alexion Pharmaceuticals in Q2 2020 and held it in 5 quarters.
Bollard Group's Alexion Pharmaceuticals position peaked at $78K in Q2 2021.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Bollard Group's 13F filing for Q3 2021, filed 12 Nov 2021.